Covered recipient · General Payments record
CHRISTOPHER M GAL
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2020–2024
$1,973.75
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $448.95 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $146.66 | 8 |
| BOSTON SCIENTIFIC CORPORATION | $125.31 | 1 |
| PENTAX OF AMERICA, INC. | $64.07 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $35.43 | 2 |
| Janssen Biotech, Inc. | $31.23 | 1 |
| QOL Medical, LLC | $29.95 | 2 |
| AIMMUNE THERAPEUTICS, INC. | $16.30 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.67 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765074 | CMS |
| ABBVIE INC. | $27.07 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765076 | CMS |
| ABBVIE INC. | $7.58 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765078 | CMS |
| ABBVIE INC. | $17.38 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765080 | CMS |
| ABBVIE INC. | $23.15 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765082 | CMS |
| ABBVIE INC. | $8.71 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765084 | CMS |
| ABBVIE INC. | $22.29 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765086 | CMS |
| ABBVIE INC. | $23.81 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103765088 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $16.30 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147001351 | CMS |
| Boston Scientific Corporation | $125.31 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092362470 | CMS |
| Janssen Biotech, Inc. | $31.23 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078332354 | CMS |
| PENTAX of America, Inc. | $35.12 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119259514 | CMS |
| PENTAX of America, Inc. | $28.95 | 02/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119259538 | CMS |
| QOL Medical, LLC | $14.91 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147719359 | CMS |
| QOL Medical, LLC | $15.04 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147719361 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.69 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137551478 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.74 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137551480 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.